Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study

Annals of the New York Academy of Sciences

Volumn 1084, Issue , 2006, Pages 304-318

  Sibal, Latika ^a   Huong, Nai Law ^b   Gebbie, Janice ^b   Home, Philip ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Neuropathy; Risk factors; Type 1 diabetes

Indexed keywords

CHOLESTEROL;

ADULT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DATA BASE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INFORMATION PROCESSING; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PREDICTION; RISK FACTOR; STATISTICAL SIGNIFICANCE; ARTICLE; DRINKING BEHAVIOR; HEART MUSCLE ISCHEMIA; INCIDENCE; MIDDLE AGED; ONSET AGE; PERIPHERAL VASCULAR DISEASE; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SMOKING;

ADULT; AGE OF ONSET; ALCOHOL DRINKING; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERIPHERAL VASCULAR DISEASES; POLYNEUROPATHIES; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 34447650793     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1372.036     Document Type: Conference Paper

References (42)

1. THOMAS, P.K. 1994. Diabetic peripheral neuropathies: their cost to patient and society and the value of knowledge of risk factors for development of interventions. Eur. Neurol. 41(Suppl 1): 35-43.
2. GORDOIS, A., P. SCUFFHAM, A. SHEARER, et al. 2003. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26: 1790-1795.
3. DYCK, P.J., J.L. DAVIES, D.M. WILSON, et al. 1999. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 22: 1479-1486.
4. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
5. THE DIABETES CONTROL AND C OMPLICATIONS TRIAL RESEARCH GROUP. 1993. The effect of intensive treatment of diabetes on the development and progression of long-termcomplications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986.
6. PIRART, J. 1978. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (part 2). Diabetes Care 1: 252-263.
7. PIRART, J. 1978. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (part 1). Diabetes Care 1: 168-188.
8. MARTIN, C.L., J. ALBERS, W.H. HERMAN, et al. & DCCT/EDIC Research Group. 2006. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 29: 340-344.
9. DYCK, P.J., W.J. LITCHY, K.A. LEHMAN, et al. 1995. Variables influencing neuropathic endpoints: the Rochester diabetic neuropathy study of healthy subjects. Neurology 45: 1115-1121.
10. TESFAYE, S., N. CHATURVEDI, S.E. EATON, et al. 2005. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 352: 341-350.
11. FORREST, K.Y., R.E. MASER, G. PAMBIANCO, et al. 1997. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 46: 665-670.
12. ZIEGLER, D., W. RATHMANN, B. HAASTERT, et al. 2005. Prevalence of polyneuropathy in impaired glucose tolerance and diabetes. The MONICA/KORA Augsburg Surveys and Myocardial Infarction Registry (KORA-A Study). Diabetologia 48(Suppl. 1): A364, Abstract 1008.
13. LEVEY, A.S., J.P. BOSCH, J.B. LEWIS, et al. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann. Intern. Med. 130: 461-470.
14. LEVEY, A., T. GREENE, J. KUSEK & G. BECK. 2000. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J. Am. Soc. Nephrol. 11: 155A.
15. FLYNN, M.D., I.A. O'BRIEN & R.J. CORRALL. 1995. The prevalence of autonomic and peripheral neuropathy in insulin-treated diabetic subjects. Diabet. Med. 12: 310-313.
16. BOULTON, A.J., G. KNIGHT, J. DRURY & J.D. WARD. 1985. The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. Diabetes Care 8: 125-128.
17. KNUIMAN, M.W., T.A. WELBORN, V.J. MCCANN, et al. 1986. Prevalence of diabetic complications in relation to risk factors. Diabetes 35: 1332-1339.
18. CABEZAS-CERRATO, J. 1998. The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. Neuropathy Spanish study group of the Spanish Diabetes Society (SDS). Diabetologia 41: 1263-1269.
19. PERKINS, B.A., D. OLALEYE, B. ZINMAN & V. BRIL. 2001. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 24: 250-256.
20. ADLER, A.I., E.J. BOYKO, J.H. AHRONI, et al. 1997. Risk factors for diabetic peripheral sensory neuropathy. results of the Seattle prospective diabetic foot study. Diabetes Care 20: 1162-1167.
21. FRANKLIN, G.M., S.M. SHETTERLY, J.A. COHEN, et al. 1994. Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley diabetes study. Diabetes Care 17: 1172-1177.
22. MASER, R.E., A.R. STEENKISTE, J.S. DORMAN, et al. 1989. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complications study. Diabetes 38: 1456-1461.
23. BARBOSA, A.P., J.L. MEDINA, E.P. RAMOS & H.P. BARROS. 2001. Prevalence and risk factors of clinical diabetic polyneuropathy in a Portuguese primary health care population. Diabet. Metab. 27: 496-502.
24. SOSENKO, J.M., M.T. GADIA, A.M. FOURNIER, et al. 1986. Body stature as a risk factor for diabetic sensory neuropathy. Am. J. Med. 80: 1031-1034.
25. BOOYA, F., F. BANDARIAN, B. LARIJANI, et al. 2005. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurol. 5: 24.
26. BIHAN, H., S. L4, C. SASS, et al. 2005. Association among individual deprivation, glycemic control, and diabetes complications: the EPICES score. Diabetes Care 28: 2680-2685.
27. YOUNG, M.J., A.J. BOULTON, A.F. MACL EOD, et al. 1993. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36: 150-154.
28. ADLER, A.I., I.M. STRATTON, H.A. NEIL, et al. 2000. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321: 412-419.
29. ZOLLI, A. 2004. Foot ulceration due to arterial insufficiency: role of cilostazol. J. Wound Care 13: 45-47.
30. WANG, T., M.B. ELAM, W.P. FORBES, et al. 2003. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis 171: 337-342.
31. REJA, A., S. TESFAYE, N.D. HARRIS & J.D. WARD. 1995. Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet. Med. 12: 307-309.
32. MALIK, R.A., S. WILLIAMSON, C. ABBOTT, et al. 1998. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 352: 1978-1981.
33. NIELSEN, V.K. 1973. The peripheral nerve function in chronic renal failure. VI. The relationship between sensory and motor nerve conduction and kidney function, azotemia, age, sex, and clinical neuropathy. Acta Med. Scand. 194: 455-462.
34. DI PAOLO, B., P. CAPPELLI, C. SPISNI, et al. 1982. New electrophysiological assessments for the early diagnosis of encephalopathy and peripheral neuropathy in chronic uraemia. Int. J. Tissue React. 4: 301-307.
35. BERENYI, M.R., B. STRAUS & O.E. MIGLIETTA. 1971. Treatment of diabetic neuropathy with clofibrate. J. Am. Geriatr. Soc. 19: 763-772.
36. CAMERON, N., M. COTTER, M. INKSTER & M. NANGLE. 2003. Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Res. Clin. Pract. 61(Suppl 1): S35-S39.
37. FRIED, L.F., K.Y. FORREST, D. ELLIS, et al. 2001. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J. Diabetes Complications 15: 113-119.
38. LIAO, J.K. 2002. Beyond lipid lowering: the role of statins in vascular protection. Int. J. Cardiol. 86: 5-18.
39. SCHRAM, M.T., N. CHATURVEDI, C.G. SCHALKWIJK, et al. 2005. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes - the EURODIAB prospective complications study. Diabetologia 48: 370-378.
40. GONZALEZ-CLEMENTE, J.M., D. MAURICIO, C. RICHART, et al. 2005. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clin. Endo. 63: 525-529.
41. NORDWALL, M., L. HYLLIENMARK & J. LUDVIGSSON. 2006. Early diabetic complications in a population of young patients with type 1 diabetes mellitus despite intensive treatment. J. Pediatr. Endocrinol. Metab. 19: 45-54.
42. KLEIN, R., B.E. KLEIN & S.E. MOSS. 1996. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann. Intern. Med. 124: 90-96.